Table 2.
Basic Characteristics of Vaccinated and Unvaccinated IBD Patients in the Matched Cohort
| Non-vaccinated (n = 707) | Vaccinated (n = 707) | P value | SMD | |
|---|---|---|---|---|
| Age (y) | 31 ± 13.0 | 31 ± 13.0 | 1 | <0.001 |
| Sex, male | 358 (50.6%) | 358 (50.6%) | 1 | <0.001 |
| Duration of follow-up after second vaccine (weeks) | 14 (2.3–20.4) | 14 (2.3–20.4) | 1 | <0.001 |
| IBD type | ||||
| CD | 485 (69%) | 485 (69%) | 1 | 1 |
| UC | 222 (31%) | 222 (31%) | 1 | 1 |
| Disease duration (y) | 8.6 (5.4–12) | 8.6 (5.4–12) | 1 | <0.001 |
| Treatment over last year | ||||
| Mesalamine | 94 (13.3%) | 114 (16.1%) | .154 | 0.080 |
| Corticosteroid | 23 (3.3%) | 16 (2.3%) | .330 | 0.060 |
| Immunomodulator | 25 (3.5%) | 35 (5.0%) | .235 | 0.070 |
| Anti-TNF | 95 (13.4%) | 107 (15.1%) | .403 | 0.049 |
| Vedolizumab | 18 (2.5%) | 30 (4.2%) | .106 | 0.094 |
| Ustekinumab | 8 (1.1%) | 12 (1.7%) | .499 | 0.048 |
| Tofacitinib | 1 (0.1%) | 2 (0.3%) | 1.0 | 0.031 |
| IBD hospitalization ever | 271 (38.3%) | 304 (43.0%) | .083 | 0.095 |
| IBD surgery ever | 65 (9.2%) | 94 (13.3%) | .018 | 0.130 |
| Corticosteroids therapy ever | 350 (49.5%) | 376 (53.2%) | .183 | 0.074 |
| Disease activity groupa,b | 1 | <0.001 | ||
| 1 | 76 (12%) | 76 (12%) | ||
| 2 | 508 (83%) | 508 (83%) | ||
| 3 | 32 (5.2%) | 32 (5.2%) |
NOTE. Count (%), mean ± standard deviation, or medians (IQR) are presented as appropriate.
CD, Crohn’s disease; IBD, inflammatory bowel diseases; SMD, standardized mean difference; TNF, tumor necrosis factor; UC, ulcerative colitis.
a
Disease activity group calculated by hierarchical clustering of laboratory results (Supplementary Table 1, Appendix 3).
b
91 pairs had no laboratory results and could not be assigned to a disease activity group.